Cobolimab is a monoclonal antibody directed against the inhibitory T-cell receptor, T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), with potential immune checkpoint inhibitory and antineoplastic activities. Cobolimab has the potential for the treatment of non-small cell lung cancer (NSCLC).